1차 출처 기록
결정급탑라인 결과
자일리오 테라퓨틱스, XTX501 1상 데이터 2027년 하반기 발표 예정
Xilio Therapeutics has provided an anticipated timeline for initial Phase 1 data for its XTX501 program, a bispecific PD-1 / masked IL-2 therapy. The company expects to report this data in the second half of 2027, contingent on the FDA clearing the investigational new drug (IND) application, which is targeted for mid-2026.
핵심 사실
출처 발췌
EX-99.1 2 xlo-ex99_1.htm EX-99.1 Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ® This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to: development timelines and anticipated milestones for Xilio’s programs; the ultimate safety, efficacy, and potential benefits of any of Xilio’s current or future product candidates in any indication; any potential indications or commercial opportunities of our product candidates; the timing and receipt of future payments under Xilio’s collaboration or partnership agreements with AbbVie and Gilead; Xilio’s preliminary, unaudi